MA-ALAKA’I-TECHNOLOGIES
Today, Alaka’i Technologies unveiled Skai, the world’s first hydrogen fuel cell powered air mobility solution designed to transform the way the world moves. From its sleek, uncluttered design, radically simple and safe electric vertical takeoff and landing (eVTOL) vehicle, to its fuel source - a system that runs entirely on hydrogen fuel cells - Skai is poised to be one of the safest, cleanest and most versatile air mobility solutions introduced to the world.
Skai’s core team members are nationally-recognized aerospace experts, engineers, and veteran pilots who have served in top-level positions at NASA, Raytheon, Beech, Cirrus, DayJet, and the Department of Defense who collaborated on the vision of solving some of the world’s most-pressing global challenges across transportation, energy and the environment. Skai is co-designed by Designworks, the design innovation studio for the BMW Group, to leverage its creative expertise to help shape a world-class vehicle. The result is Skai, stripped away of all unnecessary complexity, waste and possible points of failure, leaving the most essential elements for the craft and optimizing them for the most intuitive experience.
“This remarkably impressive team have come together to build on our collective experience to finally realize our singular, critical vision to launch Skai and transform transportation,” said Brian Morrison, Co-Founder, President and Chief Technology Officer of Alaka’i Technologies. “Skai offers practical, real-life solutions to everything from relieving traffic congestion to delivering supplies during natural disasters. Skai is set to offer affordable, realistic applications in the commercial, private, freight, and personal air mobility markets.”
The heart of Skai, and one of its most revolutionary features, is the use of hydrogen fuel cells, a clean environmental solution from end to end. With the advantage of being 95% reusable and the remaining (99%) recyclable, Skai’s hydrogen fuel cells offer reliable, safe and environmentally clean emission comprised solely of heat and water. This is a stark alternative to traditional fuel and battery sources. Hydrogen fuel cells allow Skai to travel further distances and carry a greater payload.
“Air mobility is a very exciting and fascinating topic,” said Holger Hampf, President of Designworks. “Our focus for this project was to help build a new consumer facing brand from scratch - considering and designing all touchpoints - digital, physical and service. And as a result, delivering an all-encompassing user-centric experience which is purposeful and highly desirable in all aspects.”
Alaka’i Technologies has initiated their test program with the FAA. Pending certification, Skai will create new possibilities in personal mobility for everyone, efficient emergency responses, economical freight distribution, and the utilization of hydrogen fuel cells as a highly reliable, zero-emission power source.
Skai Highlights Include:
- Co-designed by Designworks with inherent quality craftsmanship
- Powered by clean hydrogen fuel cells, with zero emissions
- Range: Up to 4 Hours, ~400 Miles
- Six reliable, quiet, efficient electric motors with designed-in redundancy
- Seats up to five passengers
- Reliable, fault-tolerant architecture for safety and security
- Piloted version launched first, with autonomous versions to follow
- Designed for the ultimate in safety, with an Airframe Parachute
For more information: http://skai.co .
ABOUT ALAKA’I
Alaka’i Technologies is an emerging air mobility design and manufacturing company, headquartered in Hopkinton MA. Founded by Brian Morrison in 2015, Alaka’i Technologies assembled a distinguished executive team with decades of aerospace development, production, executive and airspace integration experience (NASA, Raytheon, Beech Aircraft, McDonnell Douglas, Hughes, DayJet, SATSAir, Cirrus, Metro Aviation, Delta Airlines) and FAA certification experience. Working together since the 1990’s on industry-defining projects such as the NASA AGATE and SATS Programs, they also built and flew the world’s first-ever Fly-By-Light aircraft. Today, the Alaka'i team is engineering proprietary, progressive air mobility solutions to offer point A-to-Anywhere transportation that are clean, simple, safe, and accessible for everyone. Ultimately, transforming transportation through hydrogen-powered mobility.
ABOUT DESIGNWORKS
Designworks is the design innovation studio for the BMW Group. Designworks is ‘the architect of future’ — designing holistic systems that impact and improve the world we live in. Designworks inspires and challenges the companies it works with to be and stay at the forefront of their industries in design, technology and innovation. For 25 years it has been stimulating the BMW Group as well as a select group of companies with ambitious visions for the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005834/en/
Contact:
John Moore Press@alakai.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom